Search hospitals > Quebec > SHERBROOKE
CHUS - Hopital Fleurimont
Claim this profileSHERBROOKE, Quebec J1H 5N4
Global Leader in Brain Tumor
Global Leader in Prostate Cancer
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Lung Cancer
170 reported clinical trials
13 medical researchers
Summary
CHUS - Hopital Fleurimont is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Brain Tumor, Prostate Cancer, Breast Cancer, Cancer, Lung Cancer and other specialties. CHUS - Hopital Fleurimont is involved with conducting 170 clinical trials across 273 conditions. There are 13 research doctors associated with this hospital, such as Josee Brossard, Paul Bessette, MD, Frederic Lemay, and Valerie Theberge.Area of expertise
1Brain Tumor
Global LeaderStage IV
Stage II
Stage I
2Prostate Cancer
Global LeaderStage I
Stage II
Top PIs
Josee BrossardCentre Hospitalier Universitaire de Sherbrooke-Fleurimont6 years of reported clinical research
Studies Brain Tumor
Studies Cancer
22 reported clinical trials
66 drugs studied
Paul Bessette, MDCHUS - Hôpital Fleurimont5 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
8 reported clinical trials
12 drugs studied
Frederic LemayCentre Hospitalier Universitaire de Sherbrooke-Fleurimont5 years of reported clinical research
Studies Colorectal Cancer
Studies Pancreatic Adenocarcinoma
7 reported clinical trials
22 drugs studied
Valerie ThebergeCHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)2 years of reported clinical research
Studies Breast Cancer
Studies Radiotherapy
6 reported clinical trials
14 drugs studied
Clinical Trials running at CHUS - Hopital Fleurimont
Brain Tumor
Testicular cancer
Wilms Tumor
Cancer
Ovarian Carcinoma
Ovarian Tumors
Testicular Carcinoma
Ovarian Choriocarcinoma
Breast Cancer
Small Cell Lung Cancer
Stereotactic Radiosurgery vs. HA-WBRT + Memantine
for Brain Cancer
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Recruiting2 awards Phase 3
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Chemotherapy + Radiation Therapy
for Brain Cancer
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CHUS - Hopital Fleurimont?
CHUS - Hopital Fleurimont is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Brain Tumor, Prostate Cancer, Breast Cancer, Cancer, Lung Cancer and other specialties. CHUS - Hopital Fleurimont is involved with conducting 170 clinical trials across 273 conditions. There are 13 research doctors associated with this hospital, such as Josee Brossard, Paul Bessette, MD, Frederic Lemay, and Valerie Theberge.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.